Abstract
Prevalence of obesity and bronchial asthma is increasing in industrialized countries. Several studies have suggested a relationship between these disorders. Evidence comes from studies with animal models as well as epidemiologic observations. Moreover, pulmonary function parameters, genetic and hormonal factors support the hypothesis that obesity and asthma are linked. Given the enormous economic impact effective and efficient treatment strategies for both diseases are important. The present review will describe patents and recent developments in drugs directed against obesity and asthma. Potential therapeutic targets include the ORL-1 receptor, the LPA receptor, the VEGF receptor, cannaboid receptor, T cells, and protein kinases.
Keywords: Asthma, cannaboid receptor, LPA receptor, obesity, ORL-1 receptor, protein kinase, T cell, VEGF receptor
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued)
Title: Obesity and Asthma
Volume: 3 Issue: 3
Author(s): Hans-Peter Hauber and Michael Wegmann
Affiliation:
Keywords: Asthma, cannaboid receptor, LPA receptor, obesity, ORL-1 receptor, protein kinase, T cell, VEGF receptor
Abstract: Prevalence of obesity and bronchial asthma is increasing in industrialized countries. Several studies have suggested a relationship between these disorders. Evidence comes from studies with animal models as well as epidemiologic observations. Moreover, pulmonary function parameters, genetic and hormonal factors support the hypothesis that obesity and asthma are linked. Given the enormous economic impact effective and efficient treatment strategies for both diseases are important. The present review will describe patents and recent developments in drugs directed against obesity and asthma. Potential therapeutic targets include the ORL-1 receptor, the LPA receptor, the VEGF receptor, cannaboid receptor, T cells, and protein kinases.
Export Options
About this article
Cite this article as:
Hauber Hans-Peter and Wegmann Michael, Obesity and Asthma, Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) 2009; 3 (3) . https://dx.doi.org/10.2174/187221409789104773
DOI https://dx.doi.org/10.2174/187221409789104773 |
Print ISSN 1872-2148 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3334 |
Related Articles
-
Patent Selections:
Recent Patents on Inflammation & Allergy Drug Discovery Edible Transgenic Plant Vaccines for Different Diseases
Current Pharmaceutical Biotechnology Current Status of Clinical Trials for Glioblastoma
Reviews on Recent Clinical Trials Glucocorticoid Osteoporosis
Current Pharmaceutical Design Inflammation in Asthma Pathogenesis: Role of T Cells, Macrophages, Epithelial Cells and Type 2 Inflammation
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Eph as a Target in Inflammation
Endocrine, Metabolic & Immune Disorders - Drug Targets Editorial (Thematic Issue: Emerging Formulation Design and Drug Delivery Systems for Inhaled Therapy)
Current Pharmaceutical Design Therapeutic Approach to Multiple Sclerosis by Novel Oral Drugs
Recent Patents on Inflammation & Allergy Drug Discovery Chilling-Like Attacks Terminated by Slow Pathway Ablation
Current Cardiology Reviews Editorial from Editor-in-Chief: Alternative and Complementary Medicine in Pulmonary Conditions
Current Respiratory Medicine Reviews <i>Nigella sativa</i>, as Preventive Strategy in COVID-19
Current Traditional Medicine Heme Oxygenase-1 and Carbon Monoxide: Emerging Therapeutic Targets in Inflammation and Allergy
Recent Patents on Inflammation & Allergy Drug Discovery Pentapeptides as Minimal Functional Units in Cell Biology and Immunology
Current Protein & Peptide Science The Effects of Statin Therapy on the Human Airway
Drug Metabolism Letters Mechanism of Idiosyncratic Drug Reactions: Reactive Metabolites Formation, Protein Binding and the Regulation of the Immune System
Current Drug Metabolism Immunity to Tuberculosis and Novel Therapeutic Strategies
Clinical Immunology, Endocrine & Metabolic Drugs (Discontinued) Large Porous Hollow Particles: Lightweight Champions of Pulmonary Drug Delivery
Current Pharmaceutical Design Stem Cell and Idiopathic Pulmonary Fibrosis: Mechanisms and Treatment
Current Stem Cell Research & Therapy Vasoactive Intestinal Peptide Receptors: A Molecular Target in Breast and Lung Cancer
Current Pharmaceutical Design Exploring N<sup>1</sup>-p-Fluorobenzyl-Cymserine as an Inhibitor of 5-Lipoxygenase as a Candidate for Type 2 Diabetes and Neurodegenerative Disorder Treatment
CNS & Neurological Disorders - Drug Targets